A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 3 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-11-04.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 105th largest by enrollment, is one of 11 that started in 2012, is one of 65 in phase 3, and was the 61st registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 11 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 135th largest by enrollment of the 141 interventional ones that give a count, is one of 37 that started in 2012, is one of 85 in phase 3, and was the 138th registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This extension study of WA19926 will assess the long-term safety and the efficacy of RoActemra/Actemra (tocilizumab) treatment in participants with rheumatoid arthritis. Participants who have completed the core study WA19926 are eligible to participate. Participants will receive RoActemra/Actemra 8 mg/kg intravenously every 4 weeks. The anticipated time on study drug is 104 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tocilizumab [RoActemra/Actemra]
Drug page: Tocilizumab
8 mg/kg intravenously every 4 weeks for 104 weeks
Percentage of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and AEs of Special Interest (AESIs)
An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. Adverse Events of Special Interest for this study were: Serious and/or medically significant infections; myocardial infarction/Acute coronary syndrome; Gastrointestinal perforation; Malignancies; Anaphylaxis/hypersensitivity reactions; Demyelinating disorders; Stroke and Serious and/or medically significant bleeding and hepatic events.
Time frame: End of Study (Week 104 or early withdrawal)
Number of Participants With Remission, Low, Medium, and High Disease Activity, as Measured by Disease Activity Index 28 Erythrocyte Sedimentation Rate (DAS28-ESR)
The DAS28 (ESR) score is a measure of the participant's disease activity. It is calculated using the tender joint count (28 joints), swollen joint count (28 joints), erythrocyte sedimentation rate (ESR) and general health status. The DAS28-ESR scale ranges from 0 to 10, where higher scores represent higher disease activity. DAS28 \<=3.2 implied low disease activity, DAS \>3.2 to 5.1 implied moderate disease activity, DAS \>5.1 implied high disease activity, and DAS28 \<2.6 = clinical remission.
Time frame: Screening and End of Study (Week 104 or early withdrawal)
Number of Participants With Remission, Low, Medium, and High Disease Activity, as Measured by Simplified Disease Activity Index (SDAI)
The SDAI was defined as the numerical sum of 5 outcome parameters: tender and swollen joint count (based on a 28-joint assessment), participant and physician global assessment of disease activity on a 100 millimeter (mm) Visual analogue scale (VAS) (VAS; 0 = no disease activity and 100 = worst disease activity) and level of C-reactive protein (CRP) (milligram per deciliter \[mg/dl\], normal \< 1 mg/dl). SDAI total score = 0-86 where a higher score reflects worsening disease. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.
Time frame: Screening and End of Study (Week 104 or early withdrawal)
Number of Participants With Decreased, Unchanged, and Increased Tender Joint Count (TJC)
Tender joint count was performed by a skilled assessor, evaluating 68 joints for tenderness.
Time frame: Week 12 and Week 104
Number of Participants With Decreased, Unchanged, and Increased Swollen Joint Count (SJC)
Swollen joint count was performed by a skilled assessor, evaluating 66 joints for swelling.
Time frame: Week 12 and Week 104
Time to Rheumatoid Arthritis (RA) Flare
RA flare was defined as any worsening of the participant's disease activity that in the opinion of the Investigator required treatment intensification beyond supportive therapy which included restarting of the study drug treatment. Time to RA flare was defined as the period of drug-free remission until documentation of RA flare. Drug-free remission was defined as clinical remission (based on DAS28-ESR \< 2.6 and /or SDAI ≤ 3.3) for two consecutive assessment visits, followed by discontinuation of tocilizumab, at the Investigator's discretion, at the second assessment visit.
Time frame: End of Study (Week 104 or early withdrawal)
Number of Participants With Decreased, Unchanged, and Increased Participants Global Assessment of Disease Activity
The participant global assessment of disease activity was measured using a 100 mm VAS ranging from 0=very good to 100=very bad.
Time frame: Week 12 and Week 104
Number of Participants With Decreased, Unchanged, and Increased Participant Global Assessment of Pain
A participant's overall assessment of pain on a VAS was assessed with a question concerning the amount of pain due to arthritis. Pain was assessed on a 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm).
Time frame: Week 12 and Week 104
Health Assessment Questionnaire Disability Index (HAQ-DI)
The Health Assessment Questionnaire Disability Index (HAQ-DI) is a participant-completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores divided by the number of domains answered. Total possible scores range from 0 to 3, where 0=least difficulty, and 3=extreme difficulty.
Time frame: End of Study (Week 104 or early withdrawal)
| Milestone | Tocilizumab |
|---|---|
| Started | 12 |
| Completed | 4 |
| Not completed | 8 |
| Withdrew: Administrative/other | 8 |
An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. Adverse Events of Special Interest for this study were: Serious and/or medically significant infections; myocardial infarction/Acute coronary syndrome; Gastrointestinal perforation; Malignancies; Anaphylaxis/hypersensitivity reactions; Demyelinating disorders; Stroke and Serious and/or medically significant bleeding and hepatic events.
| percentage of participants | Tocilizumab |
|---|---|
| AEs | 75 |
| SAEs | 0 |
| AESI | 0 |
The DAS28 (ESR) score is a measure of the participant's disease activity. It is calculated using the tender joint count (28 joints), swollen joint count (28 joints), erythrocyte sedimentation rate (ESR) and general health status. The DAS28-ESR scale ranges from 0 to 10, where higher scores represent higher disease activity. DAS28 \<=3.2 implied low disease activity, DAS \>3.2 to 5.1 implied moderate disease activity, DAS \>5.1 implied high disease activity, and DAS28 \<2.6 = clinical remission.
| participants | Tocilizumab |
|---|---|
| Remission (Baseline) | 5 |
| Low Disease Activity (Baseline) | 1 |
| Moderate Disease Activity (Baseline) | 4 |
| High Disease Activity (Baseline) | 2 |
| Remission (End of Study) | 10 |
| Low Disease Activity (End of Study) | 1 |
| Moderate Disease Activity (End of Study) | 0 |
| High Disease Activity (End of Study) | 1 |
The SDAI was defined as the numerical sum of 5 outcome parameters: tender and swollen joint count (based on a 28-joint assessment), participant and physician global assessment of disease activity on a 100 millimeter (mm) Visual analogue scale (VAS) (VAS; 0 = no disease activity and 100 = worst disease activity) and level of C-reactive protein (CRP) (milligram per deciliter \[mg/dl\], normal \< 1 mg/dl). SDAI total score = 0-86 where a higher score reflects worsening disease. SDAI \<=3.3 indicates clinical remission, \>3.4 to 11 = low disease activity, \>11 to 26 = moderate disease activity, and \>26 = high (or severe) disease activity.
| participants | Tocilizumab |
|---|---|
| Remission (Baseline) | 0 |
| Low Disease Activity (Baseline) | 6 |
| Moderate Disease Activity (Baseline) | 3 |
| High Disease Activity (Baseline) | 3 |
| Remission (End of Study) | 3 |
| Low Disease Activity (End of Study) | 7 |
| Moderate Disease Activity (End of Study) | 1 |
| High Disease Activity (End of Study) | 1 |
Tender joint count was performed by a skilled assessor, evaluating 68 joints for tenderness.
| participants | Tocilizumab |
|---|---|
| Decreased (Week 12; n=11) | 5 |
| Unchanged (Week 12; n=11) | 4 |
| Increased (Week 12;n=11) | 2 |
| Decreased (Week 104;n=4) | 2 |
| Unchanged (Week 104;n=4) | 2 |
| Increased (Week 104;n=4) | 0 |
Swollen joint count was performed by a skilled assessor, evaluating 66 joints for swelling.
| participants | Tocilizumab |
|---|---|
| Decreased (Week 12; n=11) | 3 |
| Unchanged (Week 12; n=11) | 7 |
| Increased (Week 12;n=11) | 1 |
| Decreased (Week 104;n=4) | 2 |
| Unchanged (Week 104;n=4) | 2 |
| Increased (Week 104;n=4) | 0 |
RA flare was defined as any worsening of the participant's disease activity that in the opinion of the Investigator required treatment intensification beyond supportive therapy which included restarting of the study drug treatment. Time to RA flare was defined as the period of drug-free remission until documentation of RA flare. Drug-free remission was defined as clinical remission (based on DAS28-ESR \< 2.6 and /or SDAI ≤ 3.3) for two consecutive assessment visits, followed by discontinuation of tocilizumab, at the Investigator's discretion, at the second assessment visit.
No measurements were reported for this outcome.
The participant global assessment of disease activity was measured using a 100 mm VAS ranging from 0=very good to 100=very bad.
| participants | Tocilizumab |
|---|---|
| Decreased (Week 12; n=11) | 6 |
| Unchanged (Week 12; n=11) | 0 |
| Increased (Week 12;n=11) | 5 |
| Decreased (Week 104;n=4) | 2 |
| Unchanged (Week 104;n=4) | 0 |
| Increased (Week 104;n=4) | 2 |
A participant's overall assessment of pain on a VAS was assessed with a question concerning the amount of pain due to arthritis. Pain was assessed on a 100 mm VAS scale with a left-hand marker "no pain" (0 mm) or right-hand marker "extreme pain" (100 mm).
| participants | Tocilizumab |
|---|---|
| Decreased (Week 12; n=11) | 7 |
| Unchanged (Week 12; n=11) | 4 |
| Increased (Week 12;n=11) | 0 |
| Decreased (Week 104;n=4) | 2 |
| Unchanged (Week 104;n=4) | 0 |
| Increased (Week 104;n=4) | 2 |
The Health Assessment Questionnaire Disability Index (HAQ-DI) is a participant-completed questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. Each item was scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores divided by the number of domains answered. Total possible scores range from 0 to 3, where 0=least difficulty, and 3=extreme difficulty.
| units on a scale | Tocilizumab |
|---|---|
| Health Assessment Questionnaire Disability Index (HAQ-DI) | 1.18 ± 0.953 |
Collected over End of Study (Week 104 or early withdrawal). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab | — | 0/12 (0%) | 9/12 (75%) |
| Event | Tocilizumab |
|---|---|
| NasopharyngitisInfections and infestations | 3/12 |
| DiarrhoeaGastrointestinal disorders | 2/12 |
| DermatitisSkin and subcutaneous tissue disorders | 2/12 |
| RanulaGastrointestinal disorders | 1/12 |
| CystitisInfections and infestations | 1/12 |
| InfluenzaInfections and infestations | 1/12 |
| Otitis externaInfections and infestations | 1/12 |
| Otitis mediaInfections and infestations | 1/12 |
| Respiratory tract infectionInfections and infestations | 1/12 |
| Arthropod biteInjury, poisoning and procedural complications | 1/12 |
Analysis population included all the enrolled participants in the study.
| Age, Continuous(years) | Tocilizumab |
|---|---|
| Mean | 51.25 ± 8.67 |
| Sex: Female, Male(Participants) | Tocilizumab |
|---|---|
| Female | 8 |
| Male | 4 |
The record gives a start of Jul 2012, a primary completion of Dec 2014 and a completion of Dec 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2016, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab